ImmuPharma plc (LON:IMM – Get Free Report)’s share price was up 0.9% on Friday . The company traded as high as GBX 7.68 and last traded at GBX 6.70. Approximately 245,650 shares traded hands during trading, a decline of 93% from the average daily volume of 3,335,700 shares. The stock had previously closed at GBX 6.64.
ImmuPharma Stock Performance
The firm has a market cap of £32.68 million, a price-to-earnings ratio of -7.30 and a beta of 3.02. The firm’s 50 day moving average is GBX 7.15 and its 200-day moving average is GBX 8.32.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- A personal warning from Martin Weiss (Please read)
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
